Date: 2014-07-24
Type of information: Grant
Company: Xention (UK)
Investors: Technology Strategy Board (UK)
Amount: £1.4 million (€1.77 million)
Funding type: grant
Planned used: Xention is developing a pipeline of innovative products for the treatment of atrial fibrillation (AF) by targeting key ion channels. Using its proprietary platform, Xention has identified a series of potent and selective modulators of IKACh (inhibitors of the cardiac potassium channel). These funds will be used to support the preclinical development of Xention’s novel inhibitors of the cardiac potassium channel.
Others: * On July 24, 2014, Xention, a Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, announced that it had secured £1.4m co-funding from the Technology Strategy Board, the UK’s innovation agency, to progress its novel IKACh channel blockers through pre-clinical development.
In addition to its IKACh programme, Xention and Servier Laboratories are conducting clinical studies of XEN-D0103, a modulator of IKur (Kv1.5), another cardiac potassium channel thought to be important in AF. Xention recently granted an option to Servier to develop and commercialise XEN-D0103 in all territories except the US and Japan.
Therapeutic area: Cardiovascular diseases
